We are in a unique position to be able to make so many different vaccines at a huge volume and capacity, for an investor to come in an at a $12-13 billion valuation, it will be a fantastic deal, leaving a lot of upside.

Your name:*Required

Your email address:*Required

Pick a user name:*Required